From heart disease to neurodegeneration, Novartis makes bold deals in 2025 to expand its drug pipeline globally.

With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.

The 2025 edition of the European Society for Medical Oncology(ESMO) was held this week in Berlin, delve into its key ...

Discover eight key AI biotech deals that have been made so far in 2025, spotlighting where industry leaders are betting big.

The global biotech industry is booming, and by 2025 it will reach an estimated market worth of $729B. But while great innovation is driven by emerging biotechs, these companies often lack resources, ...

The now-annual BIOSPAIN partnering conference took place in Barcelona this week. The event attracted the biggest players in the Iberian peninsula’s biotechnology industry and an increasing number of ...

Complex regional pain syndrome (CRPS) is a rare but severe neuropathic pain condition that causes intense, long-lasting pain, often following an injury or surgery. Patients frequently report some of ...

The month of September was a big one for mergers and acquisitions (M&As) in the biotech industry. There were four billion-dollar acquisitions that were the most notable. The top buyout was Danish ...

Asabys Partners, a Spanish venture capital (VC) firm focused on healthcare, has rolled Aliath Bioventures (formerly Alta Life Sciences) into its platform in a move that boosts its assets under ...